Red cell membrane omega-3 fatty acids are decreased in nondepressed patients with social anxiety disorder

European Neuropsychopharmacology

Volumn 16, Issue 2, 2006, Pages 107-113

  Green, Pnina ^a,c   Hermesh, Haggai ^a,b   Monselise, Assaf ^c   Marom, Sofi ^b   Presburger, Gadi ^b   Weizman, Abraham ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b GEHA MENTAL HEALTH CENTER   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

Author keywords

Erythrocytes; Omega 3 fatty acids; Polyunsaturated fatty acids; Red blood cells; Social anxiety disorder; Social phobia

Indexed keywords

OMEGA 3 FATTY ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ERYTHROCYTE MEMBRANE; FEMALE; GAS LIQUID CHROMATOGRAPHY; HUMAN; MALE; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; SOCIAL PHOBIA;

ADULT; ERYTHROCYTE MEMBRANE; FATTY ACIDS; FATTY ACIDS, OMEGA-3; FATTY ACIDS, UNSATURATED; FEMALE; HUMANS; MALE; PHOBIC DISORDERS; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS;

EID: 31344470083     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2005.07.005     Document Type: Article

References (49)

1. P.B. Adams, S. Lawson, A. Sanigorski, and A.J. Sinclair Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression Lipids 31 1996 S-157 S-161
2. J. Assies, R. Lieverse, P. Vreken, R.J. Wanders, P.M. Dingemans, and D.H. Linszen Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group Biol. Psychiatry 49 2001 510 522
3. A.C. Atkinson Plots, Transformations and Regressions: Chapter 8 1985 Oxford University Press Oxford, England
4. 13C]alpha-linolenic acid to longer-chain fatty acids and partitioning towards beta-oxidation in older men Br. J. Nutr. 90 2003 311 321
5. M.C. Craig-Schmidt, K.E. Stieh, and E.L. Lien Retinal fatty acids of piglets fed docosahexaenoic and arachidonic acids from microbial sources Lipids 31 1996 53 59
6. R. Edwards, M. Peet, J. Shay, and D. Horrobin Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients J. Affect. Disord. 48 1998 149 155
7. Y.E. Finnegan, A.M. Minihane, E.C. Leigh-Firbank, S. Kew, G.W. Meijer, R. Muggli, P.P. Calder, and C.M. Williams Plant- and marine-derived n-3 polyunsaturated fatty acids have differential effects on fasting and postprandial blood lipid concentrations and on the susceptibility of LDL to oxidative modification in moderately hyperlipidemic subjects Am. J. Clin. Nutr. 77 2003 783 795
8. M.R. Fokkema, D.A.J. Brouwer, M.B. Hasperhoven, Y. Hettema, W.J.E. Bemelmans, and F.A.J. Muskiet Polyunsaturated fatty acid status of Dutch vegans and omnivores Prostaglandins Leukot. Essent. Fat. Acids 63 2000 279 285
9. M.P. Freeman, S.A. Freeman, and S.L. McElroy The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology, and treatment issues J. Affect. Disord. 68 2002 1 23
10. P. Green, and E. Yavin Natural and accelerated docosahexaenoic acid accumulation in the prenatal rat brain Lipids 31 1996 S-235 S-238
11. T. Hamazaki, S. Sawazaki, M. Itomura, E. Asaoka, Y. Nagao, N. Nishimura, K. Yazawa, T. Kuwamori, and M. Kobayashi The effect of docosahexaenoic acid on aggression in young adults J. Clin. Invest. 97 1996 1129 1133
12. A. Hara, and N.S. Radin Lipid extraction of tissue with a low-toxicity solvent Anal. Biochem. 90 1978 420 426
13. 2-mediated neurotransmitter signal transduction, in a rodent model of Parkinson's disease J. Pharmacol. Exp. Ther. 296 2001 1074 1084
14. J.R. Hibbeln, and N. Salem Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy Am. J. Clin. Nutr. 62 1995 1 9
15. J.R. Hibbeln, K.K. Makino, C.E. Martin, F. Dickerson, J. Boronow, and W.S. Fenton Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder Biol. Psychiatry 53 2003 431 441
16. 2 whole brain relaxation times in bipolar disorder Am. J. Psychiatry 161 2004 1922 1924
17. R.T. Holman The slow discovery of the importance of ω3 essential fatty acids in human health J. Nutr. 128 1998 427S 433S
18. D.F. Horrobin The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia Schizophr. Res. 30 1998 193 208
19. S.M. Innis Essential fatty acids in growth and development Prog. Lipid Res. 30 1991 39 103
20. S.M. Innis The role of dietary n-6 and n-3 fatty acids in the developing brain Dev. Neurosci. 22 2000 474 480
21. J.B. Levin, S. Marom, S. Gur, D. Wechter, and H. Hermesh Psychometric properties and three proposed subscales of a self-report version of the Liebowitz Social Anxiety Scale translated into Hebrew Depress. Anxiety 16 2002 143 151
22. S.P. Mahadik, N.S. Shendarkar, R.E. Scheffer, S. Mukherjee, and E.E. Correnti Utilization of precursor essential fatty acids in culture by skin fibroblasts from schizophrenic patients and normal controls Prostaglandins Leukot. Essent. Fat. Acids 55 1996 65 70
23. H.K. Manji, and R.H. Lenox Signaling: cellular insights into the pathophysiology of bipolar disorders Biol. Psychiatry 48 2000 518 530
24. H.K. Manji, I.I. Gottesman, and T.D. Gould Signal transduction and genes-to-behaviors pathways in psychiatric diseases Sci. STKE. 2003 (pe49)
25. S.J. Mathew, J.D. Coplan, and J.M. Gorman Neurobiological mechanisms of social anxiety disorder Am. J. Psychiatry 158 2001 1558 1567
26. D.E. Mills, Y.S. Huang, M. Narce, and J.P. Poisson Psychosocial stress, catecholamines, and essential fatty acid metabolism in rats Proc. Soc. Exp. Biol. Med. 205 1994 56 61
27. F.A.J. Muskiet, M.R. Fokkema, A. Schaafsma, E.R. Boersma, and M.A. Crawford Is docosahexaenoic acid (DHA) essential? Lessons from DHA status regulation, our ancient diet, epidemiology and randomized controlled trials J. Nutr. 134 2004 183 186
28. B. Nemets, Z. Stahl, and R.H. Belmaker Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder Am. J. Psychiatry 159 2002 477 479
29. S. Noaghiul, and J.R. Hibbeln Cross-national comparisons of seafood consumption and rates of bipolar disorders Am. J. Psychiatry 160 2003 2222 2227
30. S.J. Otto, R.H.M. de Groot, and G. Hornstra Increased risk of postpartum depressive symptoms is associated with slower normalization after pregnancy of the functional docosahexaenoic status Prostaglandins Leukot. Essent. Fat. Acids 69 2003 237 243
31. M. Peet International variations in the outcome of schizophrenia and the prevalence of depression in relation to national dietary practices: an ecological analysis Br. J. Psychiatry 184 2004 404 408
32. M. Peet, and D.F. Horrobin A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs Arch. Gen. Psychiatry 59 2002 913 919
33. M. Peet, B. Murphy, J. Shay, and D. Horrobin Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients Biol. Psychiatry 43 1998 315 319
34. A. Pelissolo, C. Andre, F. Moutard-Martin, H.U. Wittchen, and J.P. Lepine Social phobia in the community: relationship between diagnostic threshold and prevalence Eur. Psychiatr. 15 2000 25 28
35. B.K. Puri, S.J. Counsell, G. Hamilton, A.J. Richardson, and D.F. Horrobin Eicosapentaenoic acid in treatment-resistant depression associated with symptom remission, structural brain changes and reduced neuronal phospholipid turnover Int. J. Clin. Pract. 55 2001 560 563
36. P.S. Sastry Lipids of nervous tissue: composition and metabolism Prog. Lipid Res. 24 1985 69 176
37. S. Sawazaki, T. Hamazaki, K. Yazawa, and M. Kobayashi The effect of docosahexaenoic acid on plasma catecholamine concentrations and glucose tolerance during long-lasting psychological stress: a double-blind placebo-controlled study J. Nutr. Sci. Vitaminol. (Tokyo) 45 1999 655 665
38. 2 receptor binding potential in social phobia Am. J. Psychiatry 157 2000 457 459
39. D.V. Sheehan, Y. Lecrubier, K.H. Sheehan, P. Amorim, J. Janavs, E. Weiller, T. Hergueta, R. Baker, and G.C. Dunbar The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 J. Clin. Psychiatry 59 Suppl. 20 1998 22 33
40. A.P. Simopoulos Essential fatty acids in health and chronic disease Am. J. Clin. Nutr. 70 1999 560S 569S (Suppl.)
41. A.J. Sinclair, N.M. Attar-Bashi, and D. Li What is the role of α-linolenic acid for mammals? Lipids 37 2002 1113 1123
42. C. Song, X. Li, B.E. Leonard, and D.F. Horrobin Effects of dietary n-3 or n-6 fatty acids on interleukin-1b-induced anxiety, stress, and inflammatory responses in rats J. Lipid Res. 44 2003 1984 1991
43. H. Sprecher Metabolism of highly unsaturated n-3 and n-6 fatty acids Biochim. Biophys. Acta 1486 2000 219 231
44. M.B. Stein, M.R. Liebowitz, R.B. Lydiard, C.D. Pitts, W. Bushnell, and I. Gergel Paroxetine treatment of generalized social phobia (social anxiety disorder): randomized controlled trial JAMA 280 1998 708 713
45. D.J. Stein, H.G. Westenberg, and M.R. Liebowitz Social anxiety disorder and generalized anxiety disorder: serotonergic and dopaminergic neurocircuitry J. Clin. Psychiatry 63 Suppl. 6 2002 12 19
46. A.L. Stoll, W.E. Severus, M.P. Freeman, S. Rueter, H.A. Zboyan, E. Diamond, K.K. Cress, and L.B. Marangell Omega 3 fatty acids in bipolar disorder. A preliminary double-blind, placebo-controlled trial Arch. Gen. Psychiatry 56 1999 407 412
47. K.-P. Su, S.-Y. Huang, C.-C. Chiu, and W.W. Shen Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial Eur. Neuropsychopharmacol. 13 2003 267 271
48. P.E. Wainwright Dietary essential fatty acids and brain function: a developmental perspective on mechanisms Proc. Nutr. Soc. 61 2002 61 69
49. S. Watanabe, M. Doshi, and T. Hamazaki n-3 Polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice Prostaglandins Leukot. Essent. Fat. Acids 69 2003 51 59